Many people think of weight-loss drugs as a way to improve appearance or reduce body size.
However, science is now showing that some of these medicines may do much more than that. They may also help protect the heart and reduce the risk of life-threatening events like heart attacks and strokes.
A recent study led by researchers at Anglia Ruskin University explored this idea in depth. The team examined data from over 90,000 people who had taken part in major international clinical trials.
These trials tested a group of drugs known as GLP-1 receptor agonists. These medicines are commonly used to treat type 2 diabetes and, more recently, obesity.
GLP-1 drugs work by helping the body control blood sugar levels and reduce appetite. This leads to weight loss and better control of diabetes. Because obesity and diabetes are both closely linked to heart disease, researchers wanted to know whether these drugs could also reduce heart-related risks.
To answer this question, the researchers reviewed 11 large studies that focused on cardiovascular outcomes. These studies tracked patients for at least one year, with many lasting nearly three years. This long follow-up period allowed the researchers to understand the lasting effects of the drugs.
The results showed that people taking GLP-1 medications had a lower chance of experiencing major heart problems. These included heart attacks, strokes, and death related to heart disease. On average, the risk of these serious events was reduced by about 13 percent compared to people who did not take the drugs.
In addition, people on these medications were less likely to die from any cause. They also had fewer non-fatal heart attacks and strokes and were less likely to be hospitalized for heart failure. These findings suggest that the benefits of GLP-1 drugs extend well beyond their original purpose.
The study also showed that the benefits were consistent across different groups of patients. Whether someone had diabetes, obesity, or existing heart disease, the positive effects were similar. This means the drugs may be useful for a wide range of people who are at risk of cardiovascular problems.
Another important part of the study looked at safety. The researchers found no strong evidence that the drugs increased the risk of serious problems like severe low blood sugar or acute pancreatitis. However, some patients did experience side effects such as nausea and vomiting. These are common and usually improve over time.
The findings were published in the journal Cardiovascular Diabetology – Endocrinology Reports. According to lead researcher Dr. Simon Cork, this is one of the most detailed reviews of long-term studies on these drugs. He explained that the results should help doctors and patients feel more confident about their long-term use.
Reviewing the study more closely, it becomes clear why it is important. The large number of participants and the long follow-up period make the results strong and reliable. The consistency of the findings across different drugs and patient groups also adds confidence.
At the same time, there are still questions that need to be answered. For example, the long-term cost of these medications may limit access for some patients. Also, while the results are promising, lifestyle changes such as diet and exercise remain essential for overall health.
In conclusion, this research suggests that GLP-1 drugs could play a major role in future healthcare. They may help reduce the burden of heart disease, which is one of the leading causes of death worldwide.
By using these medicines alongside healthy lifestyle changes, it may be possible to prevent many serious health problems and improve quality of life for millions of people.
If you care about heart disease, please read studies that herbal supplements could harm your heart rhythm, and how eating eggs can help reduce heart disease risk.
For more health information, please see recent studies that apple juice could benefit your heart health, and results showing yogurt may help lower the death risks in heart disease.
Source: Anglia Ruskin University.
